Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study.
COVID-19
/ epidemiology
Colonoscopy
/ statistics & numerical data
Colorectal Neoplasms
/ diagnosis
Colorectal Surgery
/ statistics & numerical data
Delivery of Health Care
/ trends
Early Detection of Cancer
/ methods
England
/ epidemiology
Female
Health Services Needs and Demand
Humans
Male
Middle Aged
Patient Care Management
/ methods
Radiotherapy
/ statistics & numerical data
Referral and Consultation
/ statistics & numerical data
SARS-CoV-2
State Medicine
Journal
The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
19
11
2020
revised:
16
12
2020
accepted:
17
12
2020
pubmed:
18
1
2021
medline:
23
2
2021
entrez:
17
1
2021
Statut:
ppublish
Résumé
There are concerns that the COVID-19 pandemic has had a negative effect on cancer care but there is little direct evidence to quantify any effect. This study aims to investigate the impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England. Data were extracted from four population-based datasets spanning NHS England (the National Cancer Cancer Waiting Time Monitoring, Monthly Diagnostic, Secondary Uses Service Admitted Patient Care and the National Radiotherapy datasets) for all referrals, colonoscopies, surgical procedures, and courses of rectal radiotherapy from Jan 1, 2019, to Oct 31, 2020, related to colorectal cancer in England. Differences in patterns of care were investigated between 2019 and 2020. Percentage reductions in monthly numbers and proportions were calculated. As compared to the monthly average in 2019, in April, 2020, there was a 63% (95% CI 53-71) reduction (from 36 274 to 13 440) in the monthly number of 2-week referrals for suspected cancer and a 92% (95% CI 89-95) reduction in the number of colonoscopies (from 46 441 to 3484). Numbers had just recovered by October, 2020. This resulted in a 22% (95% CI 8-34) relative reduction in the number of cases referred for treatment (from a monthly average of 2781 in 2019 to 2158 referrals in April, 2020). By October, 2020, the monthly rate had returned to 2019 levels but did not exceed it, suggesting that, from April to October, 2020, over 3500 fewer people had been diagnosed and treated for colorectal cancer in England than would have been expected. There was also a 31% (95% CI 19-42) relative reduction in the numbers receiving surgery in April, 2020, and a lower proportion of laparoscopic and a greater proportion of stoma-forming procedures, relative to the monthly average in 2019. By October, 2020, laparoscopic surgery and stoma rates were similar to 2019 levels. For rectal cancer, there was a 44% (95% CI 17-76) relative increase in the use of neoadjuvant radiotherapy in April, 2020, relative to the monthly average in 2019, due to greater use of short-course regimens. Although in June, 2020, there was a drop in the use of short-course regimens, rates remained above 2019 levels until October, 2020. The COVID-19 pandemic has led to a sustained reduction in the number of people referred, diagnosed, and treated for colorectal cancer. By October, 2020, achievement of care pathway targets had returned to 2019 levels, albeit with smaller volumes of patients and with modifications to usual practice. As pressure grows in the NHS due to the second wave of COVID-19, urgent action is needed to address the growing burden of undetected and untreated colorectal cancer in England. Cancer Research UK, the Medical Research Council, Public Health England, Health Data Research UK, NHS Digital, and the National Institute for Health Research Oxford Biomedical Research Centre.
Sections du résumé
BACKGROUND
There are concerns that the COVID-19 pandemic has had a negative effect on cancer care but there is little direct evidence to quantify any effect. This study aims to investigate the impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England.
METHODS
Data were extracted from four population-based datasets spanning NHS England (the National Cancer Cancer Waiting Time Monitoring, Monthly Diagnostic, Secondary Uses Service Admitted Patient Care and the National Radiotherapy datasets) for all referrals, colonoscopies, surgical procedures, and courses of rectal radiotherapy from Jan 1, 2019, to Oct 31, 2020, related to colorectal cancer in England. Differences in patterns of care were investigated between 2019 and 2020. Percentage reductions in monthly numbers and proportions were calculated.
FINDINGS
As compared to the monthly average in 2019, in April, 2020, there was a 63% (95% CI 53-71) reduction (from 36 274 to 13 440) in the monthly number of 2-week referrals for suspected cancer and a 92% (95% CI 89-95) reduction in the number of colonoscopies (from 46 441 to 3484). Numbers had just recovered by October, 2020. This resulted in a 22% (95% CI 8-34) relative reduction in the number of cases referred for treatment (from a monthly average of 2781 in 2019 to 2158 referrals in April, 2020). By October, 2020, the monthly rate had returned to 2019 levels but did not exceed it, suggesting that, from April to October, 2020, over 3500 fewer people had been diagnosed and treated for colorectal cancer in England than would have been expected. There was also a 31% (95% CI 19-42) relative reduction in the numbers receiving surgery in April, 2020, and a lower proportion of laparoscopic and a greater proportion of stoma-forming procedures, relative to the monthly average in 2019. By October, 2020, laparoscopic surgery and stoma rates were similar to 2019 levels. For rectal cancer, there was a 44% (95% CI 17-76) relative increase in the use of neoadjuvant radiotherapy in April, 2020, relative to the monthly average in 2019, due to greater use of short-course regimens. Although in June, 2020, there was a drop in the use of short-course regimens, rates remained above 2019 levels until October, 2020.
INTERPRETATION
The COVID-19 pandemic has led to a sustained reduction in the number of people referred, diagnosed, and treated for colorectal cancer. By October, 2020, achievement of care pathway targets had returned to 2019 levels, albeit with smaller volumes of patients and with modifications to usual practice. As pressure grows in the NHS due to the second wave of COVID-19, urgent action is needed to address the growing burden of undetected and untreated colorectal cancer in England.
FUNDING
Cancer Research UK, the Medical Research Council, Public Health England, Health Data Research UK, NHS Digital, and the National Institute for Health Research Oxford Biomedical Research Centre.
Identifiants
pubmed: 33453763
pii: S2468-1253(21)00005-4
doi: 10.1016/S2468-1253(21)00005-4
pmc: PMC7808901
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-208Subventions
Organisme : Medical Research Council
ID : MC_PC_20062
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_18033
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/12/3/29609
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137686860
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12026/4
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
J Clin Pathol. 2021 Mar;74(3):187-189
pubmed: 32561524
Gut. 2021 Mar;70(3):537-543
pubmed: 32690602
Updates Surg. 2020 Jun;72(2):249-257
pubmed: 32436016
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Gut. 2021 Jun;70(6):1053-1060
pubmed: 32855306
J Gastrointest Surg. 2020 Oct;24(10):2357-2373
pubmed: 32607860
Int J Colorectal Dis. 2020 Dec;35(12):2219-2225
pubmed: 32728918
PLoS One. 2019 Jan 14;14(1):e0210465
pubmed: 30640932
Br J Cancer. 2013 Oct 15;109(8):2027-34
pubmed: 24045658
Radiother Oncol. 2020 Jul;148:213-215
pubmed: 32342861
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
J Surg Oncol. 2021 Jan;123(1):32-36
pubmed: 33078425
Gut. 2020 Nov;69(11):1915-1924
pubmed: 32816921
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e69-e72
pubmed: 32950351
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Br J Cancer. 2012 Oct 9;107(8):1220-6
pubmed: 22996611
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1132-1142
pubmed: 30553942
Cir Esp. 2020 Sep 1;:
pubmed: 34629479
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111